Clinical trial · Observational
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
NCT03108885CI-TRIAL-00075340terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study's Principal Investigator no longer at the institution.
Summary
Brief summary (as posted)
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Esophagus | Malignant Esophageal Neoplasm | ALIAS | 0.90 |
| Cancer of the Esophagus | Malignant Esophageal Neoplasm | ALIAS | 0.90 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Esophageal Neoplasm | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Esophageal Neoplasms Malignancy Unspecified | — | UNRESOLVED | — |
| Esophageal Neoplasms Malignant | — | UNRESOLVED | — |
| Esophagus Cancer | — | UNRESOLVED | — |
| Neoplasm, Esophageal | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood and Tissue Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Esophageal Cancer Mutation
- timeFrame
- 5 years
- description
- To identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
Secondary outcomes (1)
- measure
- Marker for Recurrence
- timeFrame
- 5 years
- description
- To validate cfDNA as a marker of recurrence of esophageal cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Esophageal Cancer any stage * Age \>18 years old * Willing and able to provide consent * No prior history of neoadjuvant therapy for the esophageal cancer Exclusion Criteria: * Age \<18 years old * Unable to provide consent
References
Publications (0)
Data not yet available
No reference posted for this study.